SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact.
复制标题
DOI:
10.1038/s41577-021-00662-4
复制
发表时间:
2022-01
期刊:
影响因子:
--
通讯作者:
Balicer RD
中科院分区:
文献类型:
--
作者:
Lipsitch M;Krammer F;Regev-Yochay G;Lustig Y;Balicer RD
Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in fully vaccinated individuals are receiving intense scrutiny because of their importance in determining how long restrictions to control virus transmission will need to remain in place in highly vaccinated populations as well as in determining the need for additional vaccine doses or changes to the vaccine formulations and/or dosing intervals. Measurement of breakthrough infections is challenging outside of randomized, placebo-controlled, double-blind field trials. However, laboratory and observational studies are necessary to understand the impact of waning immunity, viral variants and other determinants of changing vaccine effectiveness against various levels of coronavirus disease 2019 (COVID-19) severity. Here, we describe the approaches being used to measure vaccine effectiveness and provide a synthesis of the burgeoning literature on the determinants of vaccine effectiveness and breakthrough rates. We argue that, rather than trying to tease apart the contributions of factors such as age, viral variants and time since vaccination, the rates of breakthrough infection are best seen as a consequence of the level of immunity at any moment in an individual, the variant to which that individual is exposed and the severity of disease being considered. We also address key open questions concerning the transition to endemicity, the potential need for altered vaccine formulations to track viral variants, the need to identify immune correlates of protection, and the public health challenges of using various tools to counter breakthrough infections, including boosters in an era of global vaccine shortages. Here, Lipsitch and colleagues assess the impact of breakthrough SARS-CoV-2 infections that occur in individuals who have been vaccinated against COVID-19. The authors explain how the rate of breakthrough infections can be measured, what the causes of these infections are and discuss other key questions that need to be considered in light of these infections.
登录
查看更多内容
DOI:
10.1056/nejmoa2113017
发表时间:
2021-11-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
El Sahly HM;Baden LR;Essink B;Doblecki-Lewis S;Martin JM;Anderson EJ;Campbell TB;Clark J;Jackson LA;Fichtenbaum CJ;Zervos M;Rankin B;Eder F;Feldman G;Kennelly C;Han-Conrad L;Levin M;Neuzil KM;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Polakowski L;Mascola JR;Ledgerwood JE;Graham BS;August A;Clouting H;Deng W;Han S;Leav B;Manzo D;Pajon R;Schödel F;Tomassini JE;Zhou H;Miller J;COVE Study Group
通讯作者:
COVE Study Group
DOI:
10.1126/science.abm0620
发表时间:
2022-01-21
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
通讯作者:
--
DOI:
10.1038/s41577-021-00544-9
发表时间:
2021-05
期刊:
Nature reviews. Immunology
影响因子:
--
作者:
Cobey S;Larremore DB;Grad YH;Lipsitch M
通讯作者:
Lipsitch M
DOI:
10.1016/s1473-3099(21)00460-6
发表时间:
2022-01
期刊:
The Lancet. Infectious diseases
影响因子:
--
作者:
Antonelli M;Penfold RS;Merino J;Sudre CH;Molteni E;Berry S;Canas LS;Graham MS;Klaser K;Modat M;Murray B;Kerfoot E;Chen L;Deng J;Österdahl MF;Cheetham NJ;Drew DA;Nguyen LH;Pujol JC;Hu C;Selvachandran S;Polidori L;May A;Wolf J;Chan AT;Hammers A;Duncan EL;Spector TD;Ourselin S;Steves CJ
通讯作者:
Steves CJ
DOI:
10.1101/2020.06.15.153387
发表时间:
2021-01-01
期刊:
JACC. Basic to translational science
影响因子:
--
作者:
Beddingfield, Brandon J;Iwanaga, Naoki;Bix, Gregory J
通讯作者:
Bix, Gregory J